Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0SNONX
ADC Name
Milatuzumab-RSL3-NH2
Organization
University of Grenoble Alpes
Drug Status
Investigative
Indication
In total 1 Indication(s)
Diffuse large B-cell lymphoma [ICD11:2A81]
Investigative
Drug-to-Antibody Ratio
7.9
Structure
Antibody Name
Milatuzumab
  Antibody Info 
Antigen Name
HLA class II histocompatibility antigen gamma chain (CD74)
  Antigen Info 
Payload Name
RSL3-NH2
  Payload Info 
Therapeutic Target
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
  Target Info 
Linker Name
Mal-PEG4-DBCO-Ala-Val
  Linker Info 
Conjugate Type
The free thiols in the reduced mAb was conjugated to the maleimide moiety of the dibenzocyclooctyne-PEG4-maleimide.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
2.4
nM
Toledo cells
Diffuse large B-cell lymphoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 2.40 nM High CD74 expression (CD74+++)
Method Description
The inhibitory activity of Milatuzumab-RSL3-NH2 against cancer cell growth was evaluated by MTT cytotoxicity assay.
In Vitro Model Diffuse large B-cell lymphoma Toledo cells CVCL_3611
References
Ref 1 The first ADC bearing the ferroptosis inducer RSL3 as a payload with conservation of the fragile electrophilic warhead. Eur J Med Chem. 2022 Dec 15;244:114863.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.